Gilead Sciences SWOT & PESTLE Analysis

Strength

This section is available only in the 'Complete Report' on purchase.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

1. High Growth potential of Biopharmaceutical Industry: The biopharma sector has undergone momentous growth in the recent decade. It has scaled a 6,250 % growth, climbing from an annual revenue of approximately $ 4.4 billion in 1990 to $ 275 billion in 2018. This sector can be considered matured and the trends are relatively stable. The advantage of having a highly regulated market is that this environment is relatively easy to track over time, and the data can be used to access future movement more accurately. The ongoing industry trends support an optimistic view of this sector and it includes: more biopharma facilities worldwide (both major markets and Asia), more revenue and added-value for patients from innovations and processes. It also opens new opportunities of flexible manufacturing facilities including manufacturing of multiple products, automation, process control and monitoring. The current future of this industry is exciting with new technologies and markets, such as biosimilars, continuous processing, cellular and gene therapies and many more.

2. Usage of Industry 4.0 Technology: The biopharma manufacturing industry must become more streamlined and cost efficient to tackle increasing globalization and complex regulations. Adoption of Industry 4.0 technologies can provide a potential solution and there is scope to scale up implementation of these technologies in this sector. However, there are also associated challenges which can be attributed to implementation challenges in highly regulated markets, lack of knowledge required for implementation of these technologies in a scalable way within the existing systems and limited visibility of what facility should look like to be classified as best in class and if value exists for operations. However, to progress forward and implement Industry 4.0 technologies a number of factors needs to be addressed, like, risk mitigation of these technologies in highly regulated environment, quality improvement and assurance to meet the regulatory scrutiny, flexibility and scalability as per the requirement, increased productivity and increased scale-up speed and speed to market and most importantly increased innovation possibilities with the availability of new technology.

Threat

This section is available only in the 'Complete Report' on purchase.

Political

This section is available only in the 'Complete Report' on purchase.

Economic

This section is available only in the 'Complete Report' on purchase.

Social

This section is available only in the 'Complete Report' on purchase.

Technological

This section is available only in the 'Complete Report' on purchase.

Legal

This section is available only in the 'Complete Report' on purchase.

Environmental

1. Green and Sustainable Chemistry: Gilead’s manufacturing and development teams are committed towards reducing the environmental impact associated with the production of its products. Innovative and efficient ways have been adopted to minimize the usage of water, raw materials and energy in manufacturing process. The process chemistry teams which are based in Foster City, California, Edmonton, Alberta and Canada, are responsible for integrating principles of green chemistry into development of commercially viable chemical processes for the company’s Active pharmaceutical ingredients (APIs). By improving these processes, same number of APIs can be produced with fewer manufacturing batches. In 2017, the company’s chemists were able to reduce organic solvents usage by 60,000 liters and water usage by 550,000 liters in the Alberta plant. In addition, Gilead’s suppliers for APIs and drug products must follow GMP regulations as mandated by FDA and other health authorities worldwide. GMP covers testing methods, maintenance of premises and procedures, manufacturing procedures etc.

2. Waste Reduction and Recycling: A comprehensive recycling program is currently functional at Gilead’s Foster City Campus aimed at minimizing greenhouse gas emissions and landfilled waste. Employee cafeterias and other common areas are equipped with compostable cups, flatware, compost and recyclable trash bins have been provided for proper waste disposal. In 2017, 377 metric tons of hazardous waste for the foster city campus was exported and no hazardous waste was treated on-sight or shipped internationally. Based on the 2017 reports, the company was able to achieve significant waste reductions at its Edmonton campus as well, s5.4 tons of e-waste and 335 toner cartridges were recycled, 52 metric tons of organic waste was composted, 9.6 metric tons of clean wood recycled and 2.8 metric tons of construction and demolition waste was recycled. By the end of 2017, 93% of construction and demolition related waste from the research and development team was diverted from local landfills.